Research Topics
| C G WillettSummaryAffiliation: Duke University Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Chemoradiotherapy in gastrointestinal malignanciesC G Willett
Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
Clin Oncol (R Coll Radiol) 21:543-56. 2009..This overview highlights current results, controversies and potential future directions in the chemoradiotherapeutic treatment of selected gastrointestinal malignancies...- Compliance with therapeutic guidelines in Radiation Therapy Oncology Group prospective gastrointestinal clinical trialsChristopher G Willett
Duke University, Durham, United States
Radiother Oncol 105:9-13. 2012..We aim to provide insight into current standards and compliance of radiation therapy field design and administration... 
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II studyChristopher G Willett
Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
J Clin Oncol 27:3020-6. 2009..To assess the safety and efficacy of neoadjuvant bevacizumab with standard chemoradiotherapy in locally advanced rectal cancer and explore biomarkers for response...
Radiation therapy in stage II and III rectal cancerChristopher G Willett
Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
Clin Cancer Res 13:6903s-8s. 2007..Current phase III studies are evaluating novel combinations of chemotherapy and targeted agents with radiation therapy...- Targeted therapy in rectal cancerChristopher G Willett
Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27705, USA
Oncology (Williston Park) 21:1055-65; discussion 1065, 1070, 1075 passim. 2007..This review will address completed and ongoing trials that have established and continue to clarify the effects of these agents in rectal cancer... - Adjuvant therapy of pancreatic cancerChristopher G Willett
Department of Radiation Oncology and Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, NC 27705, USA
Cancer J 13:185-91. 2007..Phase III trials evaluating these modalities have led to conflicting results, leading to controversy in the use and selection of therapy. Phase II studies are now being conducted to evaluate target agent therapy with chemoradiation... - A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancerChristopher G Willett
Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
Oncologist 15:845-51. 2010..As a benchmark, we used data from an analysis of 42 patients with locally advanced rectal cancer treated with a contemporary approach of preoperative fluoropyrimidine-based radiation therapy... - Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancerChristopher G Willett
Duke University Medical Center, Durham, NC 27710, USA
Nat Clin Pract Oncol 4:316-21. 2007..The case presented here is a complete pathological response seen in a patient with extensive and locally invasive carcinoma after receiving this combined treatment... - Intraoperative radiation therapyChristopher G Willett
Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
J Clin Oncol 25:971-7. 2007..Optimally, phase III randomized trials will be carried out to prove its efficacy in these disease sites... - Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411Christopher H Crane
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
J Clin Oncol 27:4096-102. 2009..Secondary end points were toxicity, progression-free survival (PFS), and response rate (RR)... - Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancerKevin S Roof
Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA
Int J Radiat Oncol Biol Phys 65:1120-8. 2006..This article updates our experience with PFT-R, and compares these results to our experience with cisplatin, 5-FU, and radiation therapy (PF-R) in locally advanced esophageal cancer... - Intraoperative radiation therapy for locally advanced recurrent rectal or rectosigmoid cancerK Lindel
Department of Radiation Oncology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
Radiother Oncol 58:83-7. 2001..CONCLUSION: The current analysis shows the importance of a microscopic complete resection in a multi-modality approach with IORT for survival and local control. Salvage is rare for patients undergoing subtotal resection... - Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trialWilliam F Regine
Department of Radiation Oncology, University of Maryland Medical Center, Baltimore 21030, USA
JAMA 299:1019-26. 2008..Among patients with locally advanced metastatic pancreatic adenocarcinoma, gemcitabine has been shown to improve outcomes compared with fluorouracil... - Combined modality therapy for rectal and colon cancerAshish K Chawla
Department of Radiation Oncology, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114, USA
Semin Oncol 30:101-12. 2003..Active areas of investigation in CMT for colorectal cancer include the integration of biologic predictors, radiation modulators, and novel systemic agents... - Clinical research in pancreatic cancer: the Radiation Therapy Oncology Group trialsChristopher G Willett
Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
Int J Radiat Oncol Biol Phys 56:31-7. 2003..This report summarizes current and future Radiation Therapy Oncology Group clinical trials in the treatment of patients with localized pancreatic cancer... - Outcome of patients receiving radiation for cancer of the esophagus: results of the 1992-1994 Patterns of Care StudyL R Coia
Department of Radiation Oncology, Community Medical Center, Toms River, NJ 08755, USA
J Clin Oncol 18:455-62. 2000.... - Radiation therapy in the management of rectal cancerL A Kachnic
Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
Curr Opin Oncol 13:300-6. 2001..The incorporation of improved radiation planning may reduce treatment-related bowel toxicity. The integration of novel chemotherapeutic agents in the adjuvant therapy of rectal cancer remains an active area of investigation... - Current management of anal canal cancerBrian G Czito
Department of Radiation Oncology, Box 3085, Duke University Medical Center, Durham, NC 27710, USA
Curr Oncol Rep 11:186-92. 2009..Other studies are evaluating the use of capecitabine, oxaliplatin, and the anti-epidermal growth factor receptor agent cetuximab with RT in this malignancy... - Reduction of organ motion by combined cardiac gating and respiratory gatingZhiheng Wang
Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
Int J Radiat Oncol Biol Phys 68:259-66. 2007..To investigate whether the effect of organ motion can be further reduced with the application of a cardiac gating technique, together with respiratory gating... - Integration of cone-beam CT in stereotactic body radiation therapyFang Fang Yin
Department of Radiation Oncology, Duke University Medical Center, Durham NC, USA
Technol Cancer Res Treat 7:133-9. 2008..Improved immobilization may enhance positioning accuracy. Typical total "in-room" times for the patients are approximately 1 hour. CBCT-guided SBRT is feasible and enhances setup accuracy using 3-D anatomical information... - Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial resultsBrian G Czito
Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
Int J Radiat Oncol Biol Phys 68:472-8. 2007..A Phase I trial was undertaken to evaluate the combination of bevacizumab, capecitabine, oxaliplatin, and radiation therapy in patients with rectal cancer... - Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancerDan G Duda
Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
Oncologist 15:577-83. 2010..Based on the findings in this exploratory study, we propose that plasma sVEGFR-1 should be further studied as a potential biomarker to stratify patients in future studies of bevacizumab and/or cytotoxics in the neoadjuvant setting... - Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapyChris R Kelsey
Department of Radiation Oncology, Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, NC 27710, USA
Int J Radiat Oncol Biol Phys 69:1436-41. 2007..To report patterns of disease recurrence after resection of adenocarcinoma of the duodenum and compare outcomes between patients undergoing surgery only vs. surgery with concurrent chemotherapy and radiation therapy (CT-RT)... - A phase I study of UFT/leucovorin, carboplatin, and paclitaxel in combination with external beam radiation therapy for advanced esophageal carcinomaBrian G Czito
Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
Int J Radiat Oncol Biol Phys 70:1066-72. 2008..We evaluated the safety and preliminary efficacy of a combination of UFT/leucovorin, carboplatin, and paclitaxel with RT in a Phase I study of patients with advanced esophageal cancer... - Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancerChris R Kelsey
Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
Int J Radiat Oncol Biol Phys 69:770-6. 2007..To compare a neoadjuvant regimen of cisplatin/5-fluorouracil (5-FU) and concurrent radiation therapy (RT) with paclitaxel-based regimens and RT in the management of operable esophageal (EC)/gastroesophageal junction (GEJ) cancer... - Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysisJoseph M Pepek
Department of Radiation Oncology, Duke University School of Medicine, Durham, NC 27710, USA
Int J Radiat Oncol Biol Phys 78:1413-9. 2010..Intensity-modulated radiation therapy (IMRT) has the potential to reduce toxicities associated with chemoradiotherapy in the treatment of anal cancer. This study reports the results of using IMRT in the treatment of anal cancer... - Combined-modality therapy for rectal cancer: future prospectsBrian G Czito
Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
Clin Colorectal Cancer 6:625-33. 2007..These agents are now being studied with radiation therapy in the neoadjuvant therapy of rectal cancer... - Radiation therapy advances for treatment of anal cancerJoseph M Pepek
Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
J Natl Compr Canc Netw 8:123-9. 2010..This article reviews the basic principles of IMRT and highlights current literature on these recent advances and the application of new RT techniques... - The impact of advanced technologies on treatment deviations in radiation treatment deliveryLawrence B Marks
Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
Int J Radiat Oncol Biol Phys 69:1579-86. 2007..To assess the impact of new technologies on deviation rates in radiation therapy (RT)... - Commentary: rectal cancer an evolution of treatmentBrian G Czito
Radiation Oncology-Clinical Support, Box 3085 Med Ctr, Durham, North Carolina 27710, USA
Oncologist 12:1319-20. 2007 - Intensity-modulated radiation therapy for anal cancerBrian G Czito
Department of Radiation Oncology, Duke University, School of Medicine, Durham, North Carolina, USA
Oncology (Williston Park) 23:1082-9. 2009.... - Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancerLei Xu
Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
Cancer Res 69:7905-10. 2009..These data show that VEGF blockade up-regulates inflammatory pathways and NRP1, which should be evaluated as potential targets for improving anti-VEGF therapy... - Quantification of respiration-induced abdominal tumor motion and its impact on IMRT dose distributionsDavid P Gierga
Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
Int J Radiat Oncol Biol Phys 58:1584-95. 2004..The motion of tumors in the abdomen was studied using quantitative fluoroscopic analysis, and the effect on dose delivery to the target was studied... - Emerging role of intensity-modulated radiation therapy in anorectal cancerJeffrey J Meyer
Department of Radiation Oncology, Duke University Medical Center, DUMC Box 3085, Durham, NC 27710, USA
Expert Rev Anticancer Ther 8:585-93. 2008..This article reviews the rationale for its use in treating anorectal tumors and discusses early clinical data supporting its continued investigation... - Long-term results of intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancerChristopher G Willett
Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
Ann Surg 241:295-9. 2005..To analyze the effects of a treatment program of intraoperative electron beam radiation therapy (IOERT) and external beam radiation therapy and chemotherapy on the outcome of patients with unresectable or locally advanced pancreatic cancer... - Update on combined-modality treatment options for pancreatic cancerChristopher G Willett
Harvard Medical School, Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
Oncology (Williston Park) 17:29-36. 2003.... - Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancerChristopher G Willett
Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
Nat Med 10:145-7. 2004..These data indicate that VEGF blockade has a direct and rapid antivascular effect in human tumors... - Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experienceBrian G Czito
Department of Radiation Oncology, Duke University Medical Center, Box 3085, Durham, NC 27710, USA
Int J Radiat Oncol Biol Phys 62:1030-4. 2005..To better define the role of adjuvant radiation therapy and chemotherapy, a retrospective analysis of the outcome of patients undergoing surgery and adjuvant therapy was undertaken... - Locally advanced pancreatic cancerChristopher G Willett
Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
J Clin Oncol 23:4538-44. 2005..These treatments include external-beam irradiation with and without fluorouracil-based chemotherapy, intraoperative irradiation, and, more recently, external-beam irradiation with new systemic targeted agents... - Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial resultsBrian G Czito
Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
J Clin Oncol 24:656-62. 2006..We initiated two phase I trials assessing the combination of gefitinib, capecitabine, and radiation in patients with localized pancreatic and rectal cancer... - Palliative treatment of rectal cancer: is radiotherapy alone a good option?Christopher G Willett
Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
J Gastrointest Surg 8:277-9. 2004 - Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practiceChristopher G Willett
Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
Semin Oncol 33:S35-40. 2006..Phase II evaluation of bevacizumab in this setting is under way... - The national practice for patients receiving radiation therapy for carcinoma of the esophagus: results of the 1996-1999 Patterns of Care StudyMohan Suntharalingam
Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Int J Radiat Oncol Biol Phys 56:981-7. 2003..This study examined the evaluation and treatment schemes used during this time and compared these results to the PCS data obtained between 1992 and 1994 to identify any fundamental changes in national practice... - Is radiation therapy required for patients with intermediate-risk rectal cancer?Harvey Mamon
Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, MA 02115, USA
Clin Adv Hematol Oncol 5:638-44, 585. 2007..Current data permit identification of these patients, but no randomized studies have yet demonstrated that selected patients with locally advanced rectal cancer can safely be spared adjuvant or neoadjuvant radiation... - Intensity-modulated radiation therapy for anal cancer: toxicity versus outcomesTimothy M Zagar
Department of Radiation Oncology, Duke University School of Medicine, Durham, North Carolina 27705, USA
Oncology (Williston Park) 24:815-23, 828. 2010..This article reviews the relevant literature leading up to the modern treatment of anal canal cancer, and discusses IMRT-related toxicity and disease-related outcomes in the context of outcomes of conventionally treated anal cancer... - Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancersDan G Duda
Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
J Clin Oncol 25:4033-42. 2007..Finally, we offer a perspective on future research directions aimed at making this complex therapeutic approach successful in the clinic... - Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinomaJohn W Nelson
Department of Radiation Oncology, Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, NC, USA
Int J Radiat Oncol Biol Phys 73:148-53. 2009..To clarify the role of radiotherapy with chemotherapy, we performed a retrospective analysis of resected patients who had undergone chemoradiotherapy... - Intraoperative radiation therapyC G Willett
Department of Radiation Oncology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
Int J Clin Oncol 6:209-14. 2001..The future of IORT will be in the successful integration of this therapy into multimodality treatment programs of chemotherapy, external beam irradiation, and surgery for locally advanced malignancies... - Biomarkers of response and resistance to antiangiogenic therapyRakesh K Jain
Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA
Nat Rev Clin Oncol 6:327-38. 2009.... - Clinical physics, applicator choice, technique, and equipment for electron intraoperative radiation therapyPeter J Biggs
Department of Radiation Oncology, Massachusetts General Hospital, Fruit Street, Boston, MA 02114, USA
Surg Oncol Clin N Am 12:899-924. 2003..There are currently six new centers in the United States that practice IORT with a mobile linear accelerator and more than that in Europe... - The correlation between internal and external markers for abdominal tumors: implications for respiratory gatingDavid P Gierga
Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA
Int J Radiat Oncol Biol Phys 61:1551-8. 2005..Data of this type are important for image-guided therapy techniques, such as respiratory gating, that monitor the movement of external fiducials... - Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlasRobert J Myerson
Department of Radiation Oncology, Washington University, St Louis, MO, USA
Int J Radiat Oncol Biol Phys 74:824-30. 2009..To develop a Radiation Therapy Oncology Group (RTOG) atlas of the elective clinical target volume (CTV) definitions to be used for planning pelvic intensity-modulated radiotherapy (IMRT) for anal and rectal cancers... - Results of radiation therapy in gastric cancerChristopher G Willett
Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
Semin Radiat Oncol 12:170-5. 2002..Ongoing trials are now investigating new systemic agents with radiation therapy to establish efficacy compared to 5-FU and LV, as well as evaluating neoadjuvant approaches prior to resection... - VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospectsDan G Duda
Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom Street, COX 734, Boston, MA 02114, USA
Trends Mol Med 13:223-30. 2007.... - Acute and late toxicity of patients with inflammatory bowel disease undergoing irradiation for abdominal and pelvic neoplasmsC G Willett
Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
Int J Radiat Oncol Biol Phys 46:995-8. 2000..To clarify the use of this modality in this setting, this study assesses the short- and long-term tolerance of 28 patients with IBD to abdominal and pelvic irradiation... - Advances in combined radiation therapy for the management of rectal cancerLisa A Kachnic
Department of Radiation Oncology, Boston Medical Center, Boston University School of Medicine, MA 02118, USA
Expert Rev Anticancer Ther 3:471-83. 2003.... - Radiation therapy for resectable colon cancer. Is there a role in the modern chemotherapy era?Brian G Czito
Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
Oncology (Williston Park) 20:179-87; discussion 187-8, 192. 2006..Adjuvant radiation therapy should be considered in patients with colon cancer at high risk for local failure... - Radiation therapy in the treatment of cholangiocarcinomaBrian G Czito
Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
Oncology (Williston Park) 20:873-84; discussion 886-8, 893-5. 2006..Although these new approaches hold promise, the prognosis in patients with biliary cancers remains poor, and the integration of novel therapeutic strategies is indicated... - Nonoperative management of rectal cancer: current perspectivesKristin A Higgins
Department of Radiation Oncology Duke, University Medical Center, Durham, NC 27710, USA
Clin Colorectal Cancer 9:83-8. 2010..This comprehensive review summarizes the current literature regarding the nonoperative management of rectal cancer and discusses caveats and controversies to such an approach... - Radiation dose escalation in combined-modality therapy for esophageal cancerChristopher G Willett
J Clin Oncol 20:1151-3. 2002 - Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 StudyJeffrey A Meyerhardt
Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
J Clin Oncol 22:166-74. 2004..However, because these studies often lack detailed information on tumor and treatment characteristics as well as cancer recurrence, the true nature of this relation remains uncertain... - Chemotherapeutic and biologic agents as radiosensitizers in rectal cancerAndrew X Zhu
Massachusetts General Hospital, Dana-Farber/Partners Cancer Care, Harvard Medical School, Boston, MA, USA
Semin Radiat Oncol 13:454-68. 2003..In this review, we will discuss the mechanism of action and the key clinical studies of each agent as a radiosensitizer... - Management of locally advanced adenocarcinoma of the pancreasDavid P Ryan
Gastrointestinal Cancer Center, Massachusetts General Hospital, Harvard Medical School, Cox 640, 100 Blossom Street, Boston, MA 02114, USA
Hematol Oncol Clin North Am 16:95-103. 2002..The introduction of gemcitabine into chemoradiotherapy regimens may provide additional improvements in the management of patients. Preoperative therapy has proved feasible but has not shown improvement in overall survival... - Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patientsChristopher G Willett
J Clin Oncol 23:8136-9. 2005 - Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113Jaffer A Ajani
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
J Clin Oncol 26:4551-6. 2008..The primary end point was to assess whether any approach would achieve a >or= 77.5% 1-year survival rate, surpassing the historical 66% rate from the Radiation Therapy Oncology Group (RTOG) protocol 9405... - Microsatellite instability is frequently observed in rectal cancer and influenced by neoadjuvant chemoradiationMichael Y Choi
Int J Radiat Oncol Biol Phys 68:1584. 2007 - Patients undergoing treatment for pancreatic adenocarcinoma can mount an effective immune response to vaccinationsJennifer F Tseng
Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
Pancreatology 5:67-74. 2005..These data suggest that immunotherapy for pancreatic cancer may be feasible and merits further investigation... - Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancerDavid P Kelsen
Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 25:3719-25. 2007..The relationship between resection type and between tumor response and outcome were also analyzed... - A challenge to the therapeutic nihilism of ESPAC-1Mary C Koshy
Int J Radiat Oncol Biol Phys 61:965-6. 2005 - Case records of the Massachusetts General Hospital. Case 20-2005. A 58-year-old man with locally advanced pancreatic cancerDavid P Ryan
Department of Hematology and Oncology, Massachusetts General Hospital, Boston, USA
N Engl J Med 352:2734-41. 2005 - Combined modality treatment for rectal cancerAndrew X Zhu
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Semin Oncol 32:103-12. 2005..Although 5-fluorouracil (5-FU)-based chemotherapy in combination with RT remains the standard adjuvant therapy for rectal cancer, the integration of novel chemotherapeutic agents and biologic modulators is being actively investigated... - Adjuvant therapy for pancreatic cancer: an evolving paradigmAndrew X Zhu
Department of Hematology Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, 100 Blossom Street, Cox 640, Boston, MA 02114, USA
Surg Oncol Clin N Am 13:605-20, viii. 2004..This review highlights historic and current perspectives of adjuvant therapy in resected pancreatic cancer... - Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130James A Martenson
North Central Cancer Treatment Group, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
J Clin Oncol 22:3277-83. 2004..Some patients with colon cancer have a high risk of local recurrence postoperatively. This trial was undertaken to determine whether radiation therapy added to an adjuvant chemotherapy regimen improves outcome in high-risk patients... - Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 18-2004. A 61-year-old man with rectal bleeding and a 2-cm mass in the rectumPaul C Shellito
Department of Surgery, Massachusetts General Hospital, USA
N Engl J Med 350:2500-9. 2004 - Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysisLeonard L Gunderson
Radiation Oncology Department, Mayo Clinic Cancer Center, Scottsdale, AZ 85259, USA
J Clin Oncol 22:1785-96. 2004..To determine survival and relapse rates by T and N stage and treatment method in five randomized phase III North American rectal adjuvant studies... - New approaches to assessing and treating early-stage colon and rectal cancer: summary statement from 2007 Santa Monica ConferenceLee S Rosen
Premiere Oncology, Santa Monica, CA 90404, USA
Clin Cancer Res 13:6853s-6s. 2007.... - Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapyDan G Duda
Steele Laboratory for Tumor Biology, Department of Radiation Oncology and Center for Regenerative Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
J Clin Oncol 24:1449-53. 2006..CD146 is considered a panendothelial-specific marker, but its utility as a CEC marker in cancer patients remains unclear... - Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: initial observationsDushyant V Sahani
Division of Abdominal Imaging and Intervention, Department of Radiology, Massachusetts General Hospital, 55 Fruit St, White 270 F, Boston, MA 02114, USA
Radiology 234:785-92. 2005....